[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:pancreatic-ductal-adenocarcinoma:programmed-cell-death-1-ligand-1":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Pancreatic Ductal Adenocarcinoma","Programmed Cell Death 1 Ligand 1",3,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07223047","A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:55.570428Z","2026-05-05T02:35:31.728570Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07205718","A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors",[12],"2026-08-26T02:16:50.548894Z","2026-05-05T02:43:29.041246Z",{"nct_id":23,"title":24,"phases":25,"status":27,"updated_at":28,"content_modified":29},"NCT06447662","A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.",[26],"Phase 1","ACTIVE_NOT_RECRUITING","2026-08-03T03:38:39.261584Z","2026-05-05T02:43:29.038880Z"]